A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet Enema

NCT01715272 | Completed Phase 1

• 1 other identifier: NER1008-01/2012 (DBC)
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 2

Brief Summary

This study is designed to assess the difference between the performance of a new enema (TF037) against Fleet enema in distal bowel cleansing.

Conditions

Colonoscopy

Outcome Measures

Primary Outcomes (1)

• Performance of TF037 in distal bowel cleansing compared to Fleet enema using the Harefield Cleansing scale

  Between 1 to 3 hours following enema administration

Secondary Outcomes (3)

• Stool output as measured by stool weight

  up to 1 hour following enema administration

• Safety and tolerability as assessed by use of a Visual Analogue scale (VAS)

  5 and 30 minutes following enema administration

• Stool output over time

  1 hour following enema administration

Study Arms (2)

Fleet enema

ACTIVE COMPARATOR

This group will receive Fleet enema as their treatment

Drug: Fleet enema

TF037

EXPERIMENTAL

This group will receive TF037 as their treatment

Device: TF037

Interventions

TF037 DEVICE

TF037

Fleet enema DRUG

Fleet enema

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female subjects \[as determined by medical history, physical examination, laboratory test values, vital signs and 12-lead electrocardiograms (ECGs) at screening\] aged 18 to 60 years.
• Non-smokers from 3 months before enema administration and for the duration of the clinical investigation.
• Body mass index (BMI) ≥ 18 and ≤ 35 kg/m2.
• Must voluntarily provide written informed consent to participate in the clinical investigation.
• Must understand the purposes and risks of the clinical investigation and agree to follow the restrictions and schedule of procedures as defined in the clinical investigation plan, and as confirmed during the informed consent process.
• Female subjects must be postmenopausal (for at least one year and confirmed by a serum follicle stimulating hormone (FSH) test at screening), surgically sterile, practising true sexual abstinence or must use an effective method of contraception.
• Female subjects of child-bearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at check-in of each period.
• The subject's primary care physician must confirm that there is nothing in their medical history that would preclude their enrolment into this clinical investigation.
• Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).

You may not qualify if:

• Subjects with a history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease.
• Subjects with a history or presence of organic or functional gastrointestinal conditions (e.g. chronic constipation, irritable bowel syndrome, inflammatory bowel disease).
• Subjects with a clinically relevant history or presence of abnormal gastrointestinal motility.
• Subjects with a significant history of hereditary bowel disorders.
• Subjects with abnormal findings on the digital rectal examination performed at screening.
• Use of laxatives or motility altering drugs in the 3 months preceding enema administration.
• Use of any prescription or over-the-counter medication (including vitamins, herbal and mineral supplements) within 14 days prior to enema administration (or within 5 half lives if longer), with the exception of Investigator-approved hormonal contraceptives, hormone replacement therapy (HRT) and occasional paracetamol, aspirin or ibuprofen.
• Participation in a clinical drug study during the 30 days preceding enema administration in this clinical investigation.
• Donation of blood or blood products within 30 days prior to enema administration or during the clinical investigation, except as required for this clinical investigation
• Pregnant or lactating females.
• Any clinically significant illness within 28 days prior to enema administration.
• History or presence of any significant drug allergy, or a known allergy or contraindication to trisodium citrate, Fleet® enema or midazolam.
• Laboratory values at screening which are deemed to be clinically significant, unless agreed in advance by the Sponsor's Medical Representative and Principal Investigator.
• Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
• Current or history of drug or alcohol abuse within the 12 months prior to enema administration, or a positive drugs of abuse test at screening or check-in.

Sponsors & Collaborators

• Norgine: lead

Study Sites (2)

BioKinetic Europe Ltd

Belfast, Northern Ireland, BT2 7BA, United Kingdom

Location

BioKinetic Europe Ltd

Belfast, United Kingdom

Location

MeSH Terms

Interventions

sodium phosphate

Study Officials

• Ronnie Beboso, MD

  BioKinetic Europe Ltd.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: CARE PROVIDER
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 24, 2012
• First Posted: October 26, 2012
• Study Start: October 1, 2012
• Primary Completion: December 1, 2012
• Study Completion: January 1, 2013
• Last Updated: February 28, 2013

Record last verified: 2013-02

Locations

GB (2)